BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

doi:10.1016/j.ejca.2026.116674

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

European journal of cancer (Oxford, England : 1990) - 2 May 2026

Haj Mohammad Soemeya F, Spiekman Ilse A C, Verkerk Karlijn, Verbeek Florentine A J, Timmer Hans, van Maren Maud A, Zeverijn Laurien J, Geurts Birgit S, Daletzakis Antonios, Roepman Paul, Jansen Anne M L, de Leng Wendy W J, Maas Sybren L N, de Vos Filip Y F L, Verheul Henk M W, Voest Emile E, Gelderblom Hans

Abstract excerpt

INTRODUCTION: Dual MAPK pathway inhibition with dabrafenib and trametinib has demonstrated significant activity across several BRAFV600E-mutated tumor types. The aim of this study was to evaluate the efficacy and safety of dabrafenib plus trametinib in patients with BRAFV600E-mutated progressive or recurrent tumors of the central nervous system (CNS). METHODS: Adult patients with BRAFV600E-mutated CNS-tumors,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Central Nervous System Neoplasms

Share to Imidazoles

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyridones

Share to Pyrimidinones

Share to Young Adult

Source

Open in PubMed

Identifiers

PMID: 41830662
DOI: 10.1016/j.ejca.2026.116674

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.PMID 41830662Read ↗

The safety and efficacy of dabrafenib and trametinib in patients with glioma: A systematic review and meta-analysis.Semantic proximity Read ↗

The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.Semantic proximity Read ↗

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.Semantic proximity Read ↗

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.Semantic proximity Read ↗

BRAF/MEK Dual Inhibitors Therapy in Progressive and Anaplastic Pleomorphic Xanthoastrocytoma: Case Series and Literature Review.Semantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.Semantic proximity Read ↗

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.Semantic proximity Read ↗

Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.Semantic proximity Read ↗

Dabrafenib and trametinib in BRAFV600E mutated glioma.Semantic proximity Read ↗

Final analysis of a post-marketing surveillance study of dabrafenib and trametinib combination therapy in Japanese patients with unresectable malignant melanoma with BRAF V600 mutation.Semantic proximity Read ↗

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.